NCT07080658View on ClinicalTrials.gov

[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

July 23, 2023

Primary Completion Date

July 24, 2023

Study Completion Date

August 6, 2023

Conditions

COVID-19

Interventions

DRUG

[14C]-WPV01

Single oral dose of 600 mg \[14C\]-WPV01

Trial Locations (1)

Unknown

Shandong Provincial Qianfoshan Hospital, Jinan

All Listed Sponsors

lead

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

INDUSTRY